SCHEMBL30925540

SCHEMBL30925540

CN(C)c1cccnc1S(=O)(=O)Nc1cccc2c1CN(C1CC1)C2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 3/20 0.36
▸ EDNRA P25101 4/20 0.35
▸ SLC40A1 Q9NP59 5/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ NSD2 O96028 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ ADRA1A P35348 4/20 0.33
▸ GLO1 Q04760 2/20 0.31
▸ ALDH1A1 P00352 2/20 0.31
▸ AGTR1 P30556 2/20 0.31
▸ TDP1 Q9NUW8 2/20 0.31
▸ MITF O75030 1/20 0.31
▸ S1PR4 O95977 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ S1PR1 P21453 1/20 0.31
▸ OPRK1 P41145 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ CKS1B P61024 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30925503 0.86 SLC40A1 (0.39) HTR6SLC40A1ADRA1AGLO1ALDH1A1
SCHEMBL30925408 0.78 ALDH1A1 (0.40) HTR6SLC40A1KDM4ETSHRADRA1A
SCHEMBL26964541 0.77 EDNRA (0.34) HTR6EDNRASLC40A1KDM4ENSD2
SCHEMBL29800372 0.77 EDNRA (0.34) HTR6EDNRASLC40A1KDM4ENSD2
SCHEMBL30553443 0.74 HTR6 (0.33) HTR6ADRA1AALDH1A1
SCHEMBL26964497 0.74 HTR6 (0.33) HTR6ADRA1AALDH1A1
SCHEMBL30925478 0.72 CARM1 (0.34) HTR6ADRA1AALDH1A1
SCHEMBL30925521 0.72 GLO1 (0.59) SLC40A1GLO1ALDH1A1AGTR1TDP1
SCHEMBL27214186 0.72 GLO1 (0.59) SLC40A1GLO1ALDH1A1AGTR1TDP1
SCHEMBL29800922 0.72 EDNRA (0.37) HTR6EDNRASLC40A1KDM4ENSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 HTR6 3742/4885EDNRA 1570/4885SLC40A1 3357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback